And add to those PRs you mention from 2/18 onward, the previous ones that show Brilacidin's excellent safety record and indications of efficacy in three separate phase 2 trials addressing three different indications: OM, ABSSSI, and UP.
The above DD is for potential new investors to take a good look and see the explosive potential here. Brilacidin is a compound with 3 MOAs, an excellent safety record and recent in vitro COV-19 lab results that have been outstanding...